Table 2.
Treatment efficacy results.
| Characteristic | Immunotherapy | Combination | P-value |
|---|---|---|---|
| (N = 178) | (N = 147) | ||
| Best response, n (%) | |||
| Partial response | 31 (17.4) | 72 (49.0) | <1*10∧(−6) |
| Stable disease | 75 (42.1) | 62 (42.2) | |
| Progressive disease | 72 (40.4) | 13 (8.8) | |
| ORRa, n (%) [95% CI] | 27 (15.2) [9.8–20.5] | 64 (43.5) [35.4–51.6] | <1*10∧(−6) |
| DCRb, n (%) [95% CI] | 72 (40.4) [33.2–47.7] | 100 (68.0) [60.4–75.7] | 1*10∧(−6) |
| DOR, months, median (95% CI) | 21.5 (12.2–30.7) | 18.9 (NR-NR) | 0.803 |
| TTF, months, median (95% CI) | 3.6 (1.5–5.8) | 9.8 (7.5–12.1) | 1.2*10∧(−5) |
| PFS, months, median (95% CI) | 4.6 (2.1–7.1) | 15.5 (9.8–21.3) | <1*10∧(−6) |
| OS, months, median (95% CI) | 24.8 (16.3–33.3) | NR (NR-NR) | 4*10∧(−6) |
| Scores of tumor burden, mean ± SD | 1.45 ± 0.67 | 1.56 ± 0.70 | 0.284 |
a
The proportion of patients with CR or PR for at least 6 months;
b
The proportion of patients with CR or PR or SD for at least 6 months;
ORR, objective response rate; DCR, disease control rate; DOR, duration of response; TTF, time to failure; PFS, progression-free survival; OS, overall survival.